Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 OC1.5 | DOI: 10.1530/endoabs.99.OC1.5

ECE2024 Oral Communications Oral Communications 1: Reproductive and Developmental Endocrinology (6 abstracts)

Gender affirming treatment and employment rate in 3,812 Danish transgender persons and 38,120 controls. A nationwide register-based cohort study

Dorte Glintborg 1,2 , Jens-Jakob Møller 1,3 , Katrine Rubin 3,4 , Øjvind Lidegaard 5 , Guy T’Sjoen 6 , Mie-Louise Larsen 5 , Malene Hilden 5 & Marianne Andersen 1,2

1Odense University Hospital, Odense, Denmark; 2University of Southern Denmark, Klinisk Institut, Odense, Denmark; 3Odense University Hospital, OPEN, Odense, Denmark; 4University of Southern Denmark, Research unit OPEN, department of clinical research,, Odense, Denmark; 5Copenhagen University, København, Denmark; 6Ghent University Hospital, Gent, Belgium

Objective: Transgender persons often experience low socioeconomic status. Gender affirming treatment aims to improve gender dysphoria. We assessed employment rates in transgender persons compared to controls and demographic, health and treatment-related factors associated with unemployment in transgender persons.

Methods: National register-based cohort study in Danish transgender persons with diagnosis code of gender identity disorder during year 2000-2021. Five age-matched controls of the same sex at birth and five age-matched controls of the other sex at birth were included. The date of study inclusion was the first date of transgender diagnosis. Employment was the primary study outcome.

Results: The cohort included 3812 transgender persons with median age (interquartile range) 19 (15; 24) years for persons assigned female at birth (AFAB, n=1993) and 23 (19; 33) years for persons assigned male at birth (AMAB, n=1819) and 38,120 controls. Mean (standard deviation) follow up was 4.7 (4.6) years. The proportion of employment the year before study inclusion was 78.1% in transgender persons AFAB vs 91.6% female controls, and 56.2% vs 85.5% were employed after 5 years follow up. In transgender persons AMAB vs male controls, 69.1% vs 88.0% were employed the year before study inclusion and 50.4% vs 85.5% were employed after 5 years follow up. In transgender persons AFAB compared to control women, the OR (95% confidence interval) for unemployment was 2.99 (2.63; 3.40) before study inclusion and 4.14 (3.42; 5.00) in the fifth calendar year after index. In transgender persons AMAB compared to control men, corresponding ORs were 3.30 (2.93; 3.72) and 4.77 (4.04; 5.64). Use of gender affirming hormone in persons AFAB decreased probability of unemployment at all time points with OR after 5 years 0.62 (0.41; 0.93), P=0.02 (odds ratio (95% confidence interval). In persons AMAB, use of hormone treatment was not associated with changed employment rates, 5 years OR: 0.77 (0.55; 1.07), P=0.11.

Conclusion: Unemployment was more prevalent in transgender persons compared to controls. Masculinizing hormone treatment was associated with lower probability of unemployment.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.